🏛️ Verified NIH Record • Updated 2026-08-06

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) (NCT06439277)

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Eli Lilly and Company

🩺 Plain-English Summary (8th-Grade Level)

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.

Who can join: Review the eligibility criteria below.

Location: Children's Hospital Los Angeles — Los Angeles, California

Age range: 12 Years to 17 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (70 Sites)

Showing the first 25 of 70 sites.

  • Children's Hospital Los Angeles — Los Angeles, California
  • Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology — Sacramento, California
  • Nemours Children's Health - Delaware — Wilmington, Delaware
  • Medical Research Partners — Ammon, Idaho
  • Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
  • Indiana University Health University Hospital — Indianapolis, Indiana
  • UBMD Pediatrics — Buffalo, New York
  • SUNY Upstate Medical University — Syracuse, New York
  • Driscoll Children's Hospital — Corpus Christi, Texas
  • Epic Medical Research - DeSoto — DeSoto, Texas
  • Valley Institute of Research - Fort Worth — Fort Worth, Texas
  • Consano Clinical Research, LLC — Shavano Park, Texas
  • Texas Valley Clinical Research — Weslaco, Texas
  • Alliance for Multispecialty Research, LLC — Layton, Utah
  • Investigaciones Medicas Imoba Srl — Buenos Aires,
  • Centro de Investigaciones Metabólicas (CINME) — Buenos Aires,
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada — Buenos Aires,
  • Fundación Respirar — Buenos Aires,
  • DIM Clínica Privada — Ramos Mejía,
  • Centro de Investigaciones Médicas Tucuman — SAN M. de Tucuman,
  • Nightingale Research — Adelaide,
  • Cornerstone Dermatology — Coorparoo,
  • Hunter Medical Research Institute — Newcastle,
  • Perth Children's Hospital — Perth,
  • University of Sydney - Charles Perkins Centre — Sydney,

📞 Contact the Study Coordinator

Phone: (317) 615-4559

Email: LillyTrials@Lilly.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Obesity clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗